The Use of Bedaquiline in Children from Foci of Drug-Resistant Tuberculosis Infection
https://doi.org/10.37489/0235-2990-2025-70-11-12-51-57
EDN: CAIMAD
Abstract
Relevance. The increase in the incidence of drug-resistant tuberculosis necessitates the use of new etiotropic drugs. One of such contemporary drugs is bedaquiline. The literature on the safety and efficacy of bedaquiline in the treatment of tuberculosis in children of early and preschool age is limited. The aim of the study was to assess the tolerability and effectiveness of treatment regimens, including bedaquiline, in children of early and preschool age with active tuberculosis with drugresistant MBT sites. Clinical observation of 7 children of early and preschool age receiving bedaquiline included in the standard chemotherapy regimens for tuberculosis with drug-resistant pathogen sites. Results. Data were obtained on good tolerability and high clinical efficacy of bedaquiline included in standard chemotherapy regimens. Conclusion. It is advisable to continue the clinical use of bedaquiline in children of younger and preschool age.
About the Authors
T. S. Egorova
Kursk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Tatyana S. Egorova — pediatrician, phthisiologist, Children's Department for Patients with Respiratory Tuberculosis, Regional Clinical Anti-Tuberculosis Dispensary.
Kursk Region, Shchetinka village
Competing Interests:
None
N. V. Rubleva
Kursk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Natalya V. Rubleva — Ph. D. in Medicine, Chief Pediatric Phthisiologist, Ministry of Health of the Kursk Region, Head of the Children's Department for Patients with Respiratory Tuberculosis, phthisiologist, Children's Department for Patients with Respiratory Tuberculosis, Regional Clinical Anti-Tuberculosis Dispensary.
Kursk Region, Shchetinka village
Competing Interests:
None
N. M. Bryntseva
Kursk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Natalya M. Bryntseva — Head of the Children's Outpatient Department, phthisiologist, Children's Outpatient Department, Regional Clinical Tuberculosis Dispensary.
Kursk Region, Shchetinka
Competing Interests:
None
Yu. A. Zhilyaeva
Kursk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Yulia A. Zhilyaeva — Ph. D. in Medicine, Associate Professor, Department of Internal Medicine No. 2, Kursk State Medical University of the Ministry of Health of the Russian Federation.
Kursk
Competing Interests:
None
S. N. Novikova
Kursk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Svetlana N. Novikova — Ph. D. in Medicine, Associate Professor, Department of Internal Medicine of the Institute of Continuing Education, Kursk State Medical University of the Ministry of Health of the Russian Federation.
Kursk
Competing Interests:
None
Yu. I. Lebedev
Kursk State Medical University
Russian Federation
Competing Interests:
Russian Federation
Yuri I. Lebedev — Ph. D. in Medicine, Associate Professor, Department of Internal Medicine of the Institute of Continuing Education, Kursk State Medical University of the Ministry of Health of the Russian Federation.
Kursk
Competing Interests:
None
References
1. Starshinova A. A., Pavlova M. V., Yablonskii P. K., Sapozhnikova N. V., Vinogradova T. I., Chernokhaeva I. V. et al. Evolution of phthisiatry — a search for new methods and drugs effective for the treatment of tuberculosis. Prakticheskaya meditsina. 2014; 7 (83); 127–132. https://www.elibrary.ru/item.asp?id=25322933. (in Russian)
2. Barkanova O. N., Gagarina S. G., Kaluzhenina A. A., Popkova N. L. Pulmonary tuberculosis with multidrug resistance. Vestnik VolGMU. 2018; 1 (65): 23–25. https://www.elibrary.ru/item.asp?id=32723460. (in Russian)
3. Melerzanov A. V., Ivanenkov Ya. A. Innovative approach for drug design and development. Problemy Standartizatsii v Zdravookhranenii. 2017; 9–10: 55–61. https://www.elibrary.ru/item.asp?id=32237008.4. (in Russian)
4. Ruzanov D. Y.u, Skryagina E. M., Buinevich I. V., Goponyako S. V., Balasanyants G. S., Khimova E. S. New regimens and new medications in the treatment of tuberculosis: keeping step? Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2021; 1: 27–42. https://www.elibrary.ru/item.asp?id=46170156. (in Russian)
5. Kulmanov M. E., Il'in AI, Akhmetova G. K. New approach in the treatment of tuberculosis with the multidrug resistance. Modern Research of Social Problems. 2015; 9 (53): 62–82. doi: https://doi.org/10.12731/2218-7405-2015-9-5. (in Russian)
6. Saigitov R. T., Ostrovskaya A. S. Guidelines for preparation of manuscripts describing clinical cases in children: supporting the CARE and SCARE principles. Current Pediatrics. 2017; 16 (5): 352–357. doi: https://doi.org/10.15690/vsp.v16i5.1798. (in Russian)
7. Kekelidze Z. I., Trushchelev S. A. Format for presenting a clinical case report in the medical journal. Rossiiskii Psikhiatricheskii Zhurnal. 2017; 2: 54–58. https://www.elibrary.ru/item.asp?id=29044270. (in Russian)
8. Morozova T. I., Doktorova N. P., Otpushchennikova O. N., Nikolenko N. Y.u. Bedaquiline in the treatment of extensively drug-resistant tuberculosis. Pulmonologiya. 2022; 16 (4): 90–96. doi: https://doi.org/10.21518/2079-701X-2022-16-4-90-96. (In Russ).
9. Aksenova V. A., Klevno N. I., Pakhlavonova A. D., Kazakov A. V., Sokol'skaya E. A. Bedaquiline in the treatment regimen of multidrug-resistant tuberculosis (clinical observation). Meditsinskii Sovet. 2020; 17: 91–97. doi: https://doi.org/10.21518/2079-701X-2020-17-91-97. (in Russian)
10. Piskunova O. A., Panova L. V., Ovsyankina E. S. Primenenie bedakvilina v rezhimakh khimioterapii tuberkuleza organov dykhaniya s mnozhestvennoi i shirokoi lekarstvennoi ustoichivost'yu MBT u detei starshego vozrasta i podrostkov. Vestnik TsNIIT. 2022; 2 (19): 5–17. doi: https://doi.org/10.7868/S2587667822020017 (in Russian)
11. Parpieva N. N., Abulkasimov S. P., Pulatov Zh. A., Mukhtorov Sh. N., Aitzhanova A. U. Pobochnye nezhelatel'nye yavleniya pri primenenii bedakvilina v rezhime lecheniya bol'nykh s ShLU TB. Molodoi Uchenyi. 2018; 10.1 (196.1): 31–33. URL: https://moluch.ru/archive/196/49419. (in Russian)
12. Markelov Yu. M., Lesonen A. S., Kostina O. Pharmacoeconomic evaluation of treatment effectiveness after introducing a client-oriented approach for patients with primary multidrug resistant tuberculosis. Chelovek i Ego Zdorov'e. 2019; 2: 51–56. doi: https://doi.org/10.21626/vestnik/2019-2. (in Russian)
13. Lakshmanan M., Xavier A. S. Bedaquiline — the first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm. 2013; 5: 112–115. doi: 10.1016/j.jyp.2013.12.002
14. Lu P., Lill H., Bald D. ATP synthase in mycobacteria: special features and implications for a function as drug target. Biochim Biophys Acta. 1837; 2014: 1208–18. doi: 10.1016/j.bbabio.2014.01.022.
15. Matteelli A., Carvalho A. C., Dooley K. E., Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010; 5: 849–58. doi: 10.2217/fmb.10.50.
16. Haagsma A. C., Abdillahi-Ibrahim R., Wagner M. J., Krab K., Vergauwen K., Guillemont J., Andries K., Lill H., Koul A., Bald D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother. 2009; 53: 1290–1292. doi: 10.1128/AAC.01393-08.
17. Schluger N. W. Diagnosis, treatment, and prevention of drug-resistant tuberculosis.esistance in Europe: sunny days, but clouds on the horizon? Eur Respir J. 2007; 30: 825–827. doi: 10.1183/09031936.00102307.
18. Cox E., Laessig K. FDA approval of bedaquiline — the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med. 2014; 371: 689–691. doi: 10.1056/NEJMp1314385.
19. Mikhailova O. A., Drozdov V. N., Lazareva N. B., Shikh E. V. Dosage Problems in Children: Well-Known Facts and Unresolved Issues. Current Pediatrics. 2018; 17 (4): 350–355. doi: https://doi.org/10.15690/vsp.v17i4.1931. (in Russian)
20. Diacon A. H., Pym A., Grobusch M. P., de los Rios J. M., Gotuzzo E., Vasilyeva I., Leimane V., Andries K., Bakare N., De M. T., Haxaire-Theeuwes M., Lounis N., Meyvisch P., De P. E., van Heeswijk R. P., Dannemann B. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371 (8): 723–32. doi: 10.1056/NEJMoa1313865.
21. WHO European Region. Multidrug-resistant tuberculosis in children and adolescents in the Expert opinion. Copenhagen: World Health Organization. Regional Office for Europe, 2020; 38. (in Russian)
22. Bryukhacheva E. O., Lukashova E. N., Kholodov A. A., Lavryashina M. B., P'yanzova T. V. Clinical and social characteristics of the tuberculosis in children and adolescents in Kuzbass. Vestnik sovremennoi klinicheskoi meditsiny. 2022; 6: 23–28. https://www.elibrary.ru/item.asp?id=50190559. (in Russian)
23. Egorova S. N., Kondakov S. E., Gordeev V. V., Beletskii S. O., Khayatov A. R., Ikhalainen E. S. Recent problems of children pharmaceutical dosage formulation in Russian Federation. Vestnik Smolenskoi Gosudarstvennoi Meditsinskoi Akademii. 2019; 4: 220–227. https://cyberleninka.ru/article/n/sovremennye-problemy-dozirovaniya-lekarstvennyh-sredstv-dlya-detey-v-rossiyskoy-federatsii. (in Russian)
24. Krivonogova P. L., Martusevich A. K., Bitkina O. A., Kopytova T. V., Kotkova E. V. Biokhimicheskaya i kristalloskopicheskaya kharakteristika syvorotki krovi bol'nykh c tyazhelymi formami akne v dinamike lecheniya aknekutanom i roakkutanom. Fundamental'nye Issledovaniya. 2014; 7–1: 87–91. https://www.elibrary.ru/item.asp?id=21711842. (in Russian)
25. Ivanova D. A., Borisov S. E., Ivanushkina T. N., Bogorodskaya E. M., Zhuravleva M. V. Lekarstvennoe porazhenie pecheni u bol'nykh tuberkulezom: lechenie i profilaktika s pomoshch'yu gepatotropnykh preparatov. Metodicheskie rekomendatsii №111. Moscow: 2018; 50. https://rusneb.ru/catalog/000199_000009_010199682/. (in Russian)
26. Basalai O. N., Bushma M. I. Toxic nephropathy: pathogenesis, treatment, prevention. Meditsinskie Novosti. 2017; 8: 7–10. https://cyberleninka.ru/article/n/toksicheskie-nefropatii-patogenez-lechenie-profilaktika. (in Russian)
27. Litvinova M. V., Trofimov A. N., Shabanov P. D., Lebedev A. A., Bychkov E. R., Arseniev N. A., Tyukavin A. I. Molekulyarnye mekhanizmy transporta veshchestv cherez gematoentsefalicheskii bar'er kak misheni dlya farmakologicheskogo vozdeistviya. Formuly Farmatsii. 2022; 3: 82–96. https://www.elibrary.ru/item.asp?id=50747025. (in Russian)
Review
For citations:
Egorova TS, Rubleva NV, Bryntseva NM, Zhilyaeva YA, Novikova SN, Lebedev YI. The Use of Bedaquiline in Children from Foci of Drug-Resistant Tuberculosis Infection. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2025;70(11-12):51-57. (In Russ.) https://doi.org/10.37489/0235-2990-2025-70-11-12-51-57. EDN: CAIMAD
Views:
363
JATS XML
Email this article 